Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis-Reference-Cited by-同舟云学术

Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis

Published:2019-02-11 Issue:3 Volume:26 Page:312-321
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Sotirchos Elias S¹^ORCID,Gonzalez-Caldito Natalia¹,Dewey Blake E²³,Fitzgerald Kathryn C¹,Glaister Jeffrey²,Filippatou Angeliki¹^ORCID,Ogbuokiri Esther¹,Feldman Sydney¹,Kwakyi Ohemaa¹,Risher Hunter¹,Crainiceanu Ciprian⁴,Pham Dzung L²⁵⁶,Van Zijl Peter C³⁷,Mowry Ellen M¹,Reich Daniel S¹⁷⁴⁸^ORCID,Prince Jerry L²⁷,Calabresi Peter A¹,Saidha Shiv¹

Affiliation:

1. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

2. Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, USA

3. F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, USA

4. Department of Biostatistics, Johns Hopkins University, Baltimore, MD, USA

5. Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA

6. Center for Neuroscience and Regenerative Medicine, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA

7. Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

8. Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA

Abstract

Background: The effects of disease-modifying therapies (DMTs) on region-specific brain atrophy in multiple sclerosis (MS) are unclear. Objective: To determine the effects of higher versus lower efficacy DMTs on rates of brain substructure atrophy in MS. Methods: A non-randomized, observational cohort of people with MS followed with annual brain magnetic resonance imaging (MRI) was evaluated retrospectively. Whole brain, subcortical gray matter (GM), cortical GM, and cerebral white matter (WM) volume fractions were obtained. DMTs were categorized as higher (DMT-H: natalizumab and rituximab) or lower (DMT-L: interferon-beta and glatiramer acetate) efficacy. Follow-up epochs were analyzed if participants had been on a DMT for ⩾6 months prior to baseline and had at least one follow-up MRI while on DMTs in the same category. Results: A total of 86 DMT epochs (DMT-H: n = 32; DMT-L: n = 54) from 78 participants fulfilled the study inclusion criteria. Mean follow-up was 2.4 years. Annualized rates of thalamic (−0.15% vs −0.81%; p = 0.001) and putaminal (−0.27% vs −0.73%; p = 0.001) atrophy were slower during DMT-H compared to DMT-L epochs. These results remained significant in multivariate analyses including demographics, clinical characteristics, and T2 lesion volume. Conclusion: DMT-H treatment may be associated with slower rates of subcortical GM atrophy, especially of the thalamus and putamen. Thalamic and putaminal volumes are promising imaging biomarkers in MS.

Funder

Race to Erase MS

National Institutes of Health

National Multiple Sclerosis Society

Publisher

SAGE Publications

Subject

Clinical Neurology,Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458519826364

Reference36 articles.

1. Clinical Relevance of Brain Volume Measures in Multiple Sclerosis